Medication info
Emgliduo Extended Release Tablets 10/1000 mg (Empagliflozin, Metformin Hydrochloride)

Emgliduo Extended Release Tablets 10/1000 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin Amorphous›10mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Korea Prime Pharmaceutical Co., Ltd.
Appearance
Yellow rectangular extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501416 · Approved 2025.06.10 · Insurance code 663608960

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. Take 1 tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, increase the dose of metformin hydrochloride gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg and the patient's existing dose of metformin. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their existing doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is administered concomitantly with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia. No dose adjustment of this medicine is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine must be discontinued immediately. In patients 75 years of age and older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Korea Prime Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Difficulty controlling blood sugar
  • type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In particular, the combination of empagliflozin and metformin effectively manages blood sugar levels. For patients with cardiovascular disease whose blood sugar is not adequately controlled, special attention is required, and it is important to refer to relevant clinical trial information. This medication helps to provide safe and effective blood sugar management, contributing positively to diabetes treatment.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. Take 1 tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, increase the dose of metformin hydrochloride gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg and the patient's existing dose of metformin. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their existing doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is administered concomitantly with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia. No dose adjustment of this medicine is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine must be discontinued immediately. In patients 75 years of age and older, renal function and the risk of volume depletion should be considered.

Precautions

This medication helps control blood sugar. However, it should not be used in cases of poor kidney function or acute illnesses. This medication can rarely cause a condition known as lactic acidosis, which can be life-threatening, so caution is necessary. If sudden muscle pain, weakness, difficulty breathing, or abdominal pain occurs, immediate medical attention is required. Furthermore, when used with other diabetes medications, caution is necessary to avoid hypoglycemia caused by excessively low blood sugar. Urinary tract infections or genital infections may occur, so prompt treatment is necessary if infection symptoms arise. This medication can affect the body's fluid levels, necessitating special caution for patients with dehydration symptoms or the elderly. Patients with impaired liver or kidney function must consult a doctor before taking this medication and should have regular kidney function tests. Pregnant or breastfeeding women are advised not to take this medication, and those planning a pregnancy should consult a doctor. Additionally, this medication should be swallowed whole and not crushed or chewed, although the tablet coating may be expelled in stool, which is normal. It is advisable to avoid alcohol consumption while taking this medication, and patients should notify their healthcare provider of any sudden surgical procedures or radiological contrast examinations. Lastly, during the course of taking this medication, regular monitoring of blood sugar and kidney function is necessary, and immediate consultation with a healthcare provider is required if any abnormal symptoms occur.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • nausea
  • vomiting
  • diarrhea
Show 200 more
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • taste disturbance
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • perineal necrosis
  • vulvovaginitis
  • balanitis
  • decreased body fluid volume
  • fluid loss
  • increased serum creatinine
  • decreased glomerular filtration rate
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colonic bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • acute pyelonephritis
  • headache
  • cerebral infarction
  • intracranial aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • ureterolithiasis
  • acute kidney injury
  • ureterolithiasis
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • dizziness
  • chest discomfort
  • chest pain
  • weakness
  • vulvar itching
  • genital itching
  • dyslipidemia
  • low back pain
  • diabetic retinopathy
  • dry eyes
  • cough
  • shortness of breath
  • unstable angina
  • hypertension
  • insomnia
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • constipation
  • nasopharyngitis
  • herpes zoster
  • dizziness
  • headache
  • chest discomfort
  • chest pain
  • weakness
  • weight loss
  • vulvar itching
  • genital itching
  • hypoglycemia
  • decreased appetite
  • somnolence
  • diabetes mellitus
  • hyperlipidemia
  • hyponatremia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • musculoskeletal pain
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal deposits
  • retinal vein occlusion
  • lattice retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • cough
  • epistaxis
  • allergic rhinitis
  • limb injuries
  • skin lacerations
  • contusions
  • rib fractures
  • concussion
  • corneal abrasion
  • falls
  • hand fractures
  • iliolumbar ligament syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accidents
  • splenic injury
  • sternum fracture
  • skin lacerations
  • rib fractures
  • iliolumbar ligament syndrome
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • anxiety
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • positional vertigo
  • vertigo
  • otalgia
  • positional vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Yellow rectangular extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.